Protara Therapeutics, Inc. - Common Stock (TARA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
TARA on Nasdaq
Shares outstanding
51,416,160
Price per share
$7.00
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
39,817,794
Total reported value
$212,205,829
% of total 13F portfolios
0%
Share change
+13,615,963
Value change
+$73,079,091
Number of holders
103
Price from insider filings
$7.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Protara Therapeutics, Inc. - Common Stock (TARA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10% -9.1% $29,564,292 +$5,234,139 5,141,616 +22% JANUS HENDERSON GROUP PLC 31 Dec 2025
BlackRock, Inc. 4.7% -15% $12,839,266 +$1,412,386 2,408,868 +12% BlackRock, Inc. 31 Dec 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% -50% $5,974,448 -$4,423,642 1,971,765 -43% RA Capital Management, L.P. 30 Jun 2025
Opaleye Management Inc. 4.7% -12% $7,473,600 -$410,400 1,730,000 -5.2% Opaleye Management, Inc. 31 Mar 2025
CITADEL ADVISORS LLC 4.7% $7,031,811 1,627,734 Kenneth Griffin 31 Dec 2024
Woodline Partners LP 3.9% $5,751,035 1,331,258 Woodline Partners LP 31 Dec 2024

As of 31 Dec 2025, 103 institutional investors reported holding 39,817,794 shares of Protara Therapeutics, Inc. - Common Stock (TARA). This represents 77% of the company’s total 51,416,160 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Protara Therapeutics, Inc. - Common Stock (TARA) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 10% 5,141,616 +22% 0.01% $27,379,105
Velan Capital Investment Management LP 5.5% 2,834,652 +33% 8.8% $15,108,695
BlackRock, Inc. 4.7% 2,408,868 +8.1% 0% $12,839,267
VANGUARD GROUP INC 4.7% 2,391,903 +26% 0% $12,748,844
Integral Health Asset Management, LLC 4.4% 2,250,000 +61% 0.61% $11,992,500
Blackstone Inc. 3.7% 1,909,662 0% 0.04% $10,178,498
ACORN CAPITAL ADVISORS, LLC 3.4% 1,752,115 0% 3.2% $9,338,773
Sio Capital Management, LLC 3.3% 1,715,394 1.5% $9,143,050
Catalio Capital Management, LP 2.8% 1,446,254 -3.6% 1.4% $7,708,534
5AM Venture Management, LLC 2.7% 1,369,782 +71% 2.3% $7,300,938
Driehaus Capital Management LLC 2.4% 1,259,427 +183% 0.05% $6,712,746
UBS Group AG 2.4% 1,215,537 +44% 0% $6,478,812
ADAR1 Capital Management, LLC 2.2% 1,136,799 +3127% 0.45% $6,059,139
ADAGE CAPITAL PARTNERS GP, L.L.C. 2% 1,043,478 0.01% $5,561,738
BAKER BROS. ADVISORS LP 1.9% 971,614 +81% 0.03% $5,178,703
CITADEL ADVISORS LLC 1.8% 901,541 +79% 0% $4,805,214
GEODE CAPITAL MANAGEMENT, LLC 1.6% 817,196 +7.7% 0% $4,356,728
Maven Securities LTD 1.5% 754,626 0.51% $4,022,157
MILLENNIUM MANAGEMENT LLC 1.5% 753,302 +9.5% 0% $4,015,100
SPHERA FUNDS MANAGEMENT LTD. 1.3% 650,000 0.72% $3,464,500
MARSHALL WACE, LLP 1.1% 584,528 +105% 0% $3,115,534
STATE STREET CORP 1.1% 570,878 +63% 0% $3,042,780
BANK OF AMERICA CORP /DE/ 0.96% 495,904 +175% 0% $2,643,169
BURKEHILL GLOBAL MANAGEMENT, LP 0.88% 450,000 0.16% $2,398,500
SUPERSTRING CAPITAL MANAGEMENT LP 0.7% 360,000 0% 1% $1,918,800

Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 39,817,794 $212,205,829 +$73,079,091 $5.33 103
2025 Q3 26,208,473 $113,965,432 -$10,353,742 $4.35 79
2025 Q2 29,714,732 $90,054,436 +$447,680 $3.03 76
2025 Q1 28,759,849 $123,767,729 -$8,349,026 $4.26 59
2024 Q4 29,670,168 $156,599,526 +$91,818,405 $5.28 60
2024 Q3 10,445,706 $19,115,471 +$384,364 $1.83 33
2024 Q2 10,449,817 $22,236,374 +$12,029,265 $2.08 38
2024 Q1 4,570,660 $18,342,843 +$911,041 $4.01 34
2023 Q4 4,357,920 $8,168,237 -$1,261,027 $1.88 30
2023 Q3 5,117,943 $8,547,441 -$31,849 $1.67 31
2023 Q2 5,136,537 $12,262,078 -$1,134,644 $2.39 28
2023 Q1 5,503,158 $16,886,987 +$77,617 $3.13 28
2022 Q4 5,478,113 $14,679,319 -$481,288 $2.68 29
2022 Q3 5,656,228 $16,718,296 -$789,370 $2.96 26
2022 Q2 5,927,042 $18,391,293 -$2,063,463 $2.93 31
2022 Q1 6,495,468 $33,192,511 -$1,990,162 $5.11 34
2021 Q4 6,872,165 $46,492,675 +$3,840,591 $6.75 36
2021 Q3 6,311,961 $43,679,692 -$8,598,514 $6.92 36
2021 Q2 7,110,843 $69,259,000 -$22,850,218 $9.74 38
2021 Q1 8,528,460 $134,015,000 -$11,645,346 $15.74 49
2020 Q4 8,775,745 $212,476,065 -$5,829,365 $24.21 48
2020 Q3 9,281,283 $156,208,097 +$91,825,921 $16.83 44
2020 Q2 3,696,566 $108,380,809 +$108,380,809 $29.32 31